Literature DB >> 19641460

Predictors of 30-day and 1-year mortality after primary percutaneous coronary intervention for ST-elevation myocardial infarction.

Saman Rasoul1, Jan Paul Ottervanger, Menko-Jan de Boer, Jan-Henk E Dambrink, Jan C A Hoorntje, A T Marcel Gosselink, Felix Zijlstra, Harry Suryapranata, Arnoud W J van 't Hof.   

Abstract

OBJECTIVE: Predictors of 30-day mortality may differ from predictors of mortality at 1 year among 30-day survivors of ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). We aimed to evaluate the predictors of 30-day and 1-year mortality in unselected patients with STEMI treated with PCI.
METHODS: Individual patient data from 4732 patients with STEMI, who were treated with primary PCI during an 11-year study period, were recorded prospectively. Patient characteristics, 30-day, and 1-year outcome were evaluated.
RESULTS: At 30-day follow-up, 219 patients (4.6%) died; and out of the 4513 30-day survivors, 109 patients (2.8%) died at 1 year. Patients who died were older, had a higher risk profile. Higher rates of Killip class greater than 2 on admission, multivessel disease, and, more often, lower left ventricular ejection fraction were observed in patients who died. Mortality rate was 7.6% at 30 days among the females when compared with 3.7 among the males, P value less than 0.001. Age and sex-adjusted multivariate analysis revealed that previous myocardial infarction, diabetes, Killip class greater than 2, post-PCI thrombolysis in myocardial infarction flow less than 3, and left ventricular ejection fraction less than 30% were strong predictors of both 30-day and 1-year mortality. However, multivessel disease, anterior myocardial infarct location and in-hospital reinfarction, ischemic time, and pre-PCI thrombolysis in myocardial infarction flow less than 3 were particularly strong predictors of 30-day mortality.
CONCLUSION: Despite the fact that most characteristics of 30-day and 1-year mortality among 30-day survivors are similar, we found that variables that affect mortality beyond the acute phase may not necessarily be the same as those that influence early mortality.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19641460     DOI: 10.1097/MCA.0b013e32832e5c4c

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  18 in total

Review 1.  Multivessel versus culprit-only revascularization: one time versus staged procedures for the ACS population.

Authors:  Pablo Codner; Ran Kornowski
Journal:  Curr Cardiol Rep       Date:  2012-08       Impact factor: 2.931

2.  Predictors of 1-year mortality in patients with contemporary guideline-adherent therapy after acute myocardial infarction: results from the OMEGA study.

Authors:  Spyridon Liosis; Timm Bauer; Rudolf Schiele; Helmut Gohlke; Martin Gottwik; Hugo Katus; Georg Sabin; Ralf Zahn; Steffen Schneider; Bernhard Rauch; Jochen Senges; Uwe Zeymer
Journal:  Clin Res Cardiol       Date:  2013-06-06       Impact factor: 5.460

3.  Value of gated-SPECT MPI for ischemia-guided PCI of non-culprit vessels in STEMI patients with multivessel disease after primary PCI.

Authors:  Lawrence M Phillips; João V Vitola; Leslee J Shaw; Raffaele Giubbini; Ganesan Karthikeyan; Erick Alexanderson; Maurizio Dondi; Diana Paez; Amalia Peix
Journal:  J Nucl Cardiol       Date:  2018-08-01       Impact factor: 5.952

4.  Gender gap in acute coronary heart disease: Myth or reality?

Authors:  Mette Claassen; Kirsten C Sybrandy; Yolande E Appelman; Folkert W Asselbergs
Journal:  World J Cardiol       Date:  2012-02-26

5.  Differential prognostic impacts of diabetes over time course after acute myocardial infarction.

Authors:  Hack-Lyoung Kim; Si-Hyuck Kang; Chang-Hwan Yoon; Young-Seok Cho; Tae-Jin Youn; Goo-Yeong Cho; In-Ho Chae; Hyo-Soo Kim; Shung-Chull Chae; Myeong-Chan Cho; Young-Jo Kim; Ju Han Kim; Youngkeun Ahn; Myung Ho Jeong; Dong-Ju Choi
Journal:  J Korean Med Sci       Date:  2013-11-26       Impact factor: 2.153

Review 6.  Complete Versus Culprit-Only Revascularization in STEMI: a Contemporary Review.

Authors:  Daniel Y Lu; Ming Zhong; Dmitriy N Feldman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-04-07

7.  Prognostic performance of Controlling Nutritional Status score in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.

Authors:  Ahmet Zengin; Mehmet Baran Karataş; Yiğit Çanga; Gündüz Durmuş; Özge Güzelburç; Furkan Durak; Ayşe Emre
Journal:  Anatol J Cardiol       Date:  2022-01       Impact factor: 1.596

8.  Patient delay and benefit of timely reperfusion in ST-segment elevation myocardial infarction.

Authors:  Karl Heinrich Scholz; Thomas Meyer; Björn Lengenfelder; Christian Vahlhaus; Jörn Tongers; Steffen Schnupp; Rainer Burckhard; Nicolas von Beckerath; Hans-Martin Grusnick; Andreas Jeron; Klaus Dieter Winter; Sebastian K G Maier; Michael Danner; Jürgen Vom Dahl; Stefan Neef; Stefan Stefanow; Tim Friede
Journal:  Open Heart       Date:  2021-05

Review 9.  How to treat patients with ST-elevation acute myocardial infarction and multi-vessel disease?

Authors:  Petr Widimsky; David R Holmes
Journal:  Eur Heart J       Date:  2010-11-30       Impact factor: 29.983

10.  Effectiveness of percutaneous coronary intervention within 12 hours to 28 days of ST-elevation myocardial infarction in a real-world Chinese population.

Authors:  Xingli Wu; Dingyou Yang; Yusheng Zhao; Caiyi Lu; Yu Wang
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.